AI Article Synopsis
- The study addresses the challenge of drug resistance in cancer therapy by developing aminopyrrolic receptor 1 to enhance the effectiveness of satraplatin, a platinum-based drug.
- Researchers created Pluronic F127-based polyaniline nanoparticles to deliver satraplatin and the receptor together, utilizing Near Infrared laser for controlled drug release.
- The findings indicate that these nanoparticles exhibit increased cytotoxicity against cancer cells under laser irradiation, suggesting a potential new strategy to combat platinum resistance in cancer treatments.
Article Abstract
The acquired drug resistance of the platinum-based drug is a main obstacle in cancer therapy. Herein, an aminopyrrolic receptor 1 was synthesized to sensitize satraplatin for overcoming the drug resistance as well as improving tumor targeted ability. Thus, Pluronic F127-based polyaniline nanoparticles were designed to co-deliver satraplatin and aminopyrrolic receptor 1, which could control the drug release with the Near Infrared laser irradiation (808 nm) due to the polyaniline mediated photothermal conversion. Biological evaluation shows prepared nanoparticles (Pt-ARNPs) exhibited more effective cytotoxicity (IC = 2.7M) against the tested cancer cell lines under laser irradiation, compared with free satraplatin or treatment without Near-infrared radiation. Moreover, Pt-ARNPs showed comparable cytotoxicity against A549 and A549/cis cells, implying that the combination of satraplatin and aminopyrrolic receptor 1 with nano carrier might be a promising strategy to reduce platinum resistance and improve therapeutic effect in cancer therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1088/1361-6528/ac1d78 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!